Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J W Fay

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant gliomaG L Phillips, S N Wolff, J W Fay, et al.
Blood|June 1, 1980
Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cellsJ Tumen, L B Kline, J W Fay, et al.
Transfusion|November 1, 1995
Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantationR H Collins, L A Pineiro, J J Nemunaitis, et al.
Cancer Treatment Reports|May 1, 1985
Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantationH M Lazarus, R H Herzig, S N Wolff, et al.
Bone Marrow Transplantation|March 8, 2005
Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoringK Mamlouk, G Saracino, R B Berryman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1989
High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation GroupS N Wolff, R H Herzig, J W Fay, et al.
Blood|October 1, 1994
Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter studyJ W Fay, H Lazarus, R Herzig, et al.
Annals of Internal Medicine|June 15, 1993
High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant GroupS N Wolff, J W Fay, R H Herzig, et al.
Blood|March 1, 1995
High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant GroupR A Brown, S N Wolff, J W Fay, et al.
Leukemia & Lymphoma|July 1, 1996
High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant GroupR A Brown, S N Wolff, J W Fay, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1986
Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant gliomaG L Phillips, S N Wolff, J W Fay, et al.
Blood|June 1, 1980
Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cellsJ Tumen, L B Kline, J W Fay, et al.
Transfusion|November 1, 1995
Transfusion of donor buffy coat cells in the treatment of persistent or recurrent malignancy after allogeneic bone marrow transplantationR H Collins, L A Pineiro, J J Nemunaitis, et al.
Cancer Treatment Reports|May 1, 1985
Treatment of metastatic malignant melanoma with intensive melphalan and autologous bone marrow transplantationH M Lazarus, R H Herzig, S N Wolff, et al.
Bone Marrow Transplantation|March 8, 2005
Modification of the Bu/Cy myeloablative regimen using daily parenteral busulfan: reduced toxicity without the need for pharmacokinetic monitoringK Mamlouk, G Saracino, R B Berryman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1989
High-dose thiotepa with autologous bone marrow transplantation for metastatic malignant melanoma: results of phase I and II studies of the North American Bone Marrow Transplantation GroupS N Wolff, R H Herzig, J W Fay, et al.
Blood|October 1, 1994
Sequential administration of recombinant human interleukin-3 and granulocyte-macrophage colony-stimulating factor after autologous bone marrow transplantation for malignant lymphoma: a phase I/II multicenter studyJ W Fay, H Lazarus, R Herzig, et al.
Annals of Internal Medicine|June 15, 1993
High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy. A study of the American Bone Marrow Transplant GroupS N Wolff, J W Fay, R H Herzig, et al.
Blood|March 1, 1995
High-dose etoposide, cyclophosphamide, and total body irradiation with allogeneic bone marrow transplantation for patients with acute myeloid leukemia in untreated first relapse: a study by the North American Marrow Transplant GroupR A Brown, S N Wolff, J W Fay, et al.
Leukemia & Lymphoma|July 1, 1996
High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant GroupR A Brown, S N Wolff, J W Fay, et al.
Pageof 6